Urologic Cancers News
Frail patients are more likely than non-frail patients to experience adverse perioperative outcomes after radical cystectomy, a study found.
One type thermal ablation appeared superior for cT1 a renal cell carcinoma patients.
Investigators observed no differences in surgery time, blood loss, and hospital stay, with deferred vs upfront cytoreductive nephrectomy.
Among patients with non-muscle-invasive bladder cancer, those with diabetes and HbA1c levels below 7% have shorter progression-free survival.
In a population-based study, PN was associated with improved cancer-specific survival by 56%.
In a meta-analysis, partial and radical nephrectomy were associated with similar long-term overall survival, but cancer-specific survival was better with radical nephrectomy.
Outside of clinical trials, targeted therapies for advanced renal cell carcinoma in Medicare patients are associated with modest survival advantages over non-targeted therapies.
The data suggest that OS may actually be worse for patients receiving pazopanib following surgery for metastatic RCC.
The expression of interferon-related genes in tumor specimens was associated with response to neoadjuvant immune checkpoint inhibitor-based therapy.
In a phase 2 study, patients with metastatic urothelial carcinoma who had stable disease on first-line platinum-based chemotherapy experienced a delay in disease progression when switched to pembolizumab.
An FDA pooled analysis suggests that certain AEs were associated with response and overall survival in PD-1/PD-L1-treated urothelial cancer.
Nivolumab plus ipilimumab, both checkpoint inhibitors, exhibit promising anti-tumor activity in patients with advanced renal cell carcinoma with brain metastases, researchers report.
Efficacy benefits of pembrolizumab plus axitinib over sunitinib were also observed in patients with disease characterized by sarcomatoid features.
The investigators said the data justify and support the submission of enfortumab vedotin for consideration under FDA’s accelerated approval pathway.
The identification of biomarkers of response and resistance to immune checkpoint inhibitors remains an active area of research.
Hysterectomy-corrected uterine cancer incidence rates show that nonendometrioid carcinoma rates have been increasing among all women.
In this study, more than 40% of patients with metastatic RCC showed signs of hypothyroidism following 2 weeks of treatment with sunitinib.
No overall survival benefit has yet been seen with the regimen in RCC.
Among postmenopausal women, former smokers have a reduced risk for bladder cancer within the first 10 years of cessation.
Researchers report long-term follow-up results showing no significant difference in oncologic outcomes among partial nephrectomy, radiofrequency ablation, and cryoablation for cT1 renal tumors.